Last reviewed · How we verify
AL2846 capsules
AL2846 is a small-molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival.
AL2846 is a small-molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival. Used for Oncology indication (specific tumor type not publicly confirmed).
At a glance
| Generic name | AL2846 capsules |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While the exact molecular target of AL2846 has not been widely disclosed in public literature, it is being developed by Chia Tai Tianqing Pharmaceutical Group as an oncology therapeutic in Phase 3 clinical trials. The drug is designed to inhibit aberrant signaling pathways that drive malignant cell growth.
Approved indications
- Oncology indication (specific tumor type not publicly confirmed)
Common side effects
Key clinical trials
- A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma (PHASE3)
- Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer (PHASE1, PHASE2)
- Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer (PHASE2)
- Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. (PHASE3)
- A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (PHASE1, PHASE2)
- A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer (PHASE1, PHASE2)
- A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors (PHASE1)
- A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |